Clinical Trials Browser

Phase 2 × Terminated × Urethral Neoplasms × Clear all

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Phase 2 Terminated

142 enrolled 13 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

NCT00022633 2016-08-11

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Phase 2 Terminated

65 enrolled 14 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00112905 2014-05-30

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Phase 2 Terminated

27 enrolled 8 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00087295 2012-11-02

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Terminated

Urinary Bladder Neoplasms, Urethral Neoplasms